Additionally, the 36-month beta value for NRXP is 1.19. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NRXP is 7.64M and currently, short sellers hold a 6.69% ratio of that float. The average trading volume of NRXP on May 06, 2024 was 250.99K shares.
NRXP) stock’s latest price update
NRX Pharmaceuticals Inc (NASDAQ: NRXP)’s stock price has soared by 48.63 in relation to previous closing price of 2.10. Nevertheless, the company has seen a loss of -12.08% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-25 that The latest trading day saw NRx Pharmaceuticals, Inc. (NRXP) settling at $3.14, representing a +0.64% change from its previous close.
NRXP’s Market Performance
NRX Pharmaceuticals Inc (NRXP) has experienced a -12.08% fall in stock performance for the past week, with a -41.11% drop in the past month, and a -21.77% drop in the past quarter. The volatility ratio for the week is 19.36%, and the volatility levels for the past 30 days are at 12.35% for NRXP. The simple moving average for the past 20 days is -16.26% for NRXP’s stock, with a -16.42% simple moving average for the past 200 days.
NRXP Trading at -30.55% from the 50-Day Moving Average
After a stumble in the market that brought NRXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.99% of loss for the given period.
Volatility was left at 12.35%, however, over the last 30 days, the volatility rate increased by 19.36%, as shares sank -49.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.82% lower at present.
During the last 5 trading sessions, NRXP fell by -21.69%, which changed the moving average for the period of 200-days by -31.46% in comparison to the 20-day moving average, which settled at $3.59. In addition, NRX Pharmaceuticals Inc saw -32.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NRXP starting from Hurvitz Chaim, who purchase 70,000 shares at the price of $0.29 back on Aug 30 ’23. After this action, Hurvitz Chaim now owns 570,000 shares of NRX Pharmaceuticals Inc, valued at $20,125 using the latest closing price.
Gorovitz Aaron, the Director of NRX Pharmaceuticals Inc, purchase 35,000 shares at $0.32 during a trade that took place back on Aug 30 ’23, which means that Gorovitz Aaron is holding 105,000 shares at $11,196 based on the most recent closing price.
Stock Fundamentals for NRXP
Current profitability levels for the company are sitting at:
- -3479.62 for the present operating margin
- 0.38 for the gross margin
The net margin for NRX Pharmaceuticals Inc stands at -3969.25. The total capital return value is set at 2.37. Equity return is now at value -682.61, with -182.00 for asset returns.
Based on NRX Pharmaceuticals Inc (NRXP), the company’s capital structure generated -3.56 points at debt to capital in total, while cash flow to debt ratio is standing at -2.36. The debt to equity ratio resting at -0.78. The interest coverage ratio of the stock is -16.15.
Currently, EBITDA for the company is -27.58 million with net debt to EBITDA at -0.16. When we switch over and look at the enterprise to sales, we see a ratio of 5108.52. The receivables turnover for the company is 1.33for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.36.
Conclusion
In conclusion, NRX Pharmaceuticals Inc (NRXP) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
